Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defensin beta 136 (DEFB136)
- Target
- DEFB136
- Molecular classification
- Antimicrobial peptide, Beta defensin family, Cysteine-rich cationic protein, Secreted peptide
01
Overview
Defensin beta 136 (DEFB136) is a secreted, cysteine-rich cationic antimicrobial peptide belonging to the beta defensin family, located in the defensin gene cluster on human chromosome 8p23. Beta-defensins, including DEFB136, act as components of the innate immune system, exerting their effect primarily through broad-spectrum antimicrobial activity against bacteria and fungi, and may also modulate immune cell behavior. DEFB136 is reported to be preferentially expressed in the male reproductive tract, where it contributes to both local immunity and immunomodulation. No drugs are currently known to act specifically via DEFB136, but its properties are of research interest for anti-infective and immunomodulatory strategies.
- Other names
- DEFB136Defensin, beta 136Beta-defensin 136DEFB137
02
Mechanism of action
Direct disruption of microbial membranes via cationic interaction and pore formation; Immune signaling/chemotactic activity for recruiting immune cells, as described for other beta-defensins
03
Biological functions
Antimicrobial activity (active against Gram-negative and Gram-positive bacteria)Antifungal innate immune responseImmunomodulatory role (may influence immune cell recruitment and modulate inflammation)Lipopolysaccharide binding
04
Disease associations
Infection (protection against microbial colonization, especially in mucosal surfaces)Inflammation (potential roles in mucosal inflammatory states, but specific associations for DEFB136 are limited)Other (potentially male reproductive immunity and fertility, based on expression patterns)
05
Safety considerations
No specific concerns identified for DEFB136 pharmacological modulationGeneral challenges for defensin-based therapy include stability, selectivity, and potential cytotoxicity at elevated doses
Beyond the preview
Go deeper on Defensin beta 136 (DEFB136).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Defensin beta 136 (DEFB136).